BiotechTube

Obinutuzumab

Phase 2Active
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Marginal Zone Lymphoma

Conditions

Marginal Zone Lymphoma

Trial Timeline

Nov 23, 2018 → Jan 1, 2027

NCT ID
NCT03322865

About Obinutuzumab

Obinutuzumab is a phase 2 stage product being developed by Roche for Marginal Zone Lymphoma. The current trial status is active. This product is registered under clinical trial identifier NCT03322865. Target conditions include Marginal Zone Lymphoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (10)

NCT IDPhaseStatus
NCT05050214Phase 2Active
NCT04034056Pre-clinicalCompleted
NCT04059081Phase 2UNKNOWN
NCT03322865Phase 2Active
NCT03229382Phase 2Terminated
NCT03374137Pre-clinicalCompleted
NCT03153514Phase 2Terminated
NCT03059251Pre-clinicalCompleted
NCT01680991Phase 1Completed
NCT00517530Phase 1/2Completed

Competing Products

10 competing products in Marginal Zone Lymphoma

See all competitors
ProductCompanyStageHype Score
Copanlisib + RituximabCelltrionPhase 2
52
Rituximab + PembrolizumabCelltrionPhase 2
52
Pirtobrutinib + RituximabEli LillyPhase 2
52
EpcoritamabAbbViePhase 2
52
Rituximab + VenetoclaxAbbViePhase 2
52
VAY736 + lenalidomideNovartisPhase 1
33
PI3K inhibitor BKM120 + rituximabNovartisPhase 1
33
UmbralisibTG TherapeuticsPhase 2
49
HMPL-689HUTCHMEDPhase 2
47
Loncastuximab tesirine 150 µg/Kg + Loncastuximab tesirine 75µg/KgADC TherapeuticsPhase 2
44

Other Products from Roche

EmicizumabApproved
85
rituximab + methotrexate + methylprednisolone + acetaminophen + antihistamineApproved
85
RituximabApproved
85
mycophenolate mofetil [CellCept]Approved
85
saquinavir/ritonavir + atazanavir/ritonavirApproved
85